Swk Hldgs Corp Stock Price, News & Analysis

SWK Holdings (Nasdaq:SWKH), a specialty finance company focused on life science sector, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025, after market close.

The company will host a conference call to discuss the results on Friday, August 15, 2025, at 10:00am ET. Investors can join via phone using dial-in numbers (888)-506-0062 (domestic) or (973)-528-0011 (international) with participant code 117203, or through the live webcast. A replay will be available on SWK Holdings' website after the call.

Callodine Group has appointed Winston Black as Head of Life Sciences Finance Strategy to lead the firm's structured investments in the life sciences sector. Black brings over 25 years of investment experience and has invested more than $1 billion in similar strategies. Previously, he served as Co-Founder, CEO, and Chairman of SWK Holdings (NASDAQ: SWKH) from 2012 to 2022.

Black's prior experience includes co-founding PBS Capital Management and managing a $2.3 billion healthcare portfolio at Highland Capital Management. The appointment aligns with Callodine's strategy to expand in specialized private credit markets. Callodine Group, based in Boston, currently manages over $20 billion in assets across affiliated advisers.

SWK Holdings Corporation (SWKH), a life science-focused specialty finance company serving small- and mid-sized commercial-stage companies, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 earnings after market close on Thursday, May 15, 2025, followed by a conference call on Friday, May 16, 2025, at 10:00am ET.

Investors can join the conference call using the dial-in numbers (888)-506-0062 for domestic callers or (973)-528-0011 for international participants, with participant code 903493. A live webcast will be available, and a replay will be accessible on the SWK Holdings website after the call.

SWK Holdings (NASDAQ:SWKH) has completed the previously announced sale of its royalty assets to SCOF SPV I, LP, a Soleus Capital Management affiliate, for $34.0 million in cash proceeds. Following this transaction, the company's Board has declared a special cash dividend of $4.00 per share, with a record date of April 24, 2025, and payment scheduled for May 8, 2025.

The transaction value aligns with the GAAP carrying value of the royalty assets. CEO Jody Staggs highlighted that SWK maintains a strong position with an approximately $220 million performing life science loan portfolio generating attractive cash yields.

SWK Holdings (NASDAQ:SWKH) has announced the monetization of its royalty portfolio through two significant transactions. ANI Pharmaceuticals exercised its Iluvien royalty buyout option on March 17, 2025, resulting in a $17.3 million payment to SWK. Additionally, SWK has entered into an agreement with Soleus Capital to sell its remaining performing royalty portfolio for approximately $34.0 million in cash.

The combined monetization value of approximately $51.3 million represents a gain of $1.0 million over the portfolio's book value of $50.3 million as of December 31, 2024. The Soleus transaction is expected to close in two weeks, subject to customary conditions. SWK plans to declare a dividend to shareholders following the Soleus transaction closing, with the amount and record date to be announced at that time.

SWK Holdings (NASDAQ:SWKH) reported strong financial results for Q4 2024, with GAAP net income reaching $5.9 million ($0.48 per diluted share), up from $2.8 million in Q4 2023. Total revenue increased 25% to $12.4 million.

Key financial metrics include:

• Finance receivables segment revenue up 11.6% to $10.3 million
• Net finance receivables of $277.8 million, up 1.2% year-over-year
• Effective yield increased to 15.5%, up 150 basis points
• GAAP book value per share rose 5% to $23.45
• Non-GAAP tangible financing book value per share increased 8.3% to $21.15

The company monetized its performing royalty portfolio for approximately $51.3 million and plans to declare a dividend upon closing the final transaction. Portfolio improvements include successful workout conclusions and new financing agreements, including a $15 million commitment with Impedimed and an expanded $30 million credit facility with Eton.

SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company serving small- and mid-sized commercial-stage companies, has scheduled its fourth quarter and full year 2024 financial results announcement. The earnings release will be issued after market close on Wednesday, March 19, 2025.

The company will host a conference call to discuss its corporate and financial results on Thursday, March 20, 2025 at 10:00am ET. Investors can join via phone using the dial-in numbers (888)-506-0062 for domestic or (973)-528-0011 for international calls, with participant code 698628. A live webcast will also be available, and a replay will be accessible on the SWK Holdings website after the call.

ImpediMed has secured a five-year $15 million growth capital facility from SWK Holdings (NASDAQ:SWKH) to support its commercialization efforts. The company's SOZO® Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) technology for breast cancer-related lymphedema (BCRL) assessment, currently has U.S. health payor coverage for over 258 million lives.

The funding strengthens ImpediMed's capital base for executing its commercial strategy. In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its standards to include lymphedema prevention programs using BIS, validating the technology's importance in lymphedema management and creating expansion opportunities for SOZO across breast cancer centers nationwide.

SWK Holdings (NASDAQ:SWKH) has provided a comprehensive portfolio update highlighting significant transactions from Q4 2024. The company made several new originations, including a $5.0M advance to Journey Medical, $0.6M to Biotricity (with 600,000 warrants), an $8.0M senior secured loan to Triple Ring Technologies, $2.5M to SKNV, a $25.7M facility expansion with Eton (with 289,736 warrants), and $2.5M to MedMinder.

On the repayments side, SWK received $4.1M from Exeevo's asset sale, $13.0M from Biolase's bankruptcy estate, $1.9M from Trio Healthcare, $4.2M from Veru's FC2 Female Condom sale, and $12.2M final payment from Moleculight. Additional payments are expected in 2025 from various sources, including Exeevo earn-outs and the Biolase estate.